Mar. 25 at 2:40 PM
$AMGN I like AMGN and other big biotechs long term, but wanted to alert you of a company reporting ER and pivotal news after close TODAY. Tiny company (ICU) has the first meaningful improvement in treating Acute Kidney Injury in decades. Already being used with children, and adults soon (50x market size).
$9 Million MC, with a TAM in the Billions (read that again). 90% margins.
Ramping up product which will become Standard of Care for a number of conditions involving hyper-inflammation and sepsis (AKI, Cardiorenal, burn victims, transplant patients, COVID/respiratory).
Saves lives of AKI patients and ELIMINATES dialysis dependency.
Total addressable market 2B-20B.
Zero debt.
Ample runway.
Pivotal adult AKI study to be completed in 9 months.
Being used at Mayo Clinic, Cinci Childrens, UCSF, Dallas Childrens, dozens more hospitals.
6 (SIX!) Breakthrough Device Designations.
So, 9M MC for a company that will be worth Billions in a few years.
$BDX $PFE $MRNA $TAK
